- Company
- Enhertu quickly lands at general hospitals in Korea
- by Eo, Yun-Ho Feb 3, 2023 05:53am
- Prescription of the next-generation new antibody-drug conjugate 'Enhertu' has started in earnest. According to industry sources, Enhertu (trastuzumab deruxtecan), AstraZeneca and Daiichi Sankyo Korea’s new antibody-drug conjugate drug for HER2-positive breast cancer have passed the drug committees (DCs) of 20 medical institutions in Kore
- Company
- Generic for Forxiga competition in the 90 Billion market
- by Kim, Jin-Gu Feb 3, 2023 05:53am
- The patent for "Forxiga," a large diabetes treatment that produces more than 90 billion won a year, was completely lifted by the Supreme Court ruling. It is expected that patent challengers will release Forxiga generic in two months. Competition for generics is expected to intensify when the sales ban period ends in January next year due to
- Company
- Hanmi’s Rolontis makes USD 10 million in 3 mths
- by Kim, Jin-Gu Feb 2, 2023 05:48am
- Hanmi Pharmaceutical’s partner Spectrum Pharmaceuticals issued a press release announcing that “’Rovedon (Korean brand name: Rolontis)’ that the company had launched in October last year made an estimated sales of KRW 10 million in 3 months.” Spectrum plans to release details of the results on Rolvedon in its Fiscal Year 2022 Earni
- Company
- Takeda's Exkivity launches as non-reimbursement
- by Eo, Yun-Ho Feb 1, 2023 05:52pm
- EGFR Exxon 20 insertion mutation target anticancer drug Exkivity, which is eaten by Takeda Pharmaceutical Korea, will be released as non-reimbursement in February. EGFR Exxon20 insertion mutation Non-small Cell Lung Cancer treatment Exkivity targets biomarkers such as Rybrevant of Janssen Korea, but there is a difference in that it is an oral
- Company
- JW Pharma develops new drugs with Merck Life Science
- by Lee, Seok-Jun Feb 1, 2023 05:55am
- JW Pharma is expanding AI technology from new drugs to raw drug research fields to increase R&D efficiency. JW Pharma announced on the 30th that it recently signed a business agreement with Merck Life Science in Germany to research and develop raw materials for new drugs using AI. Merck offers its AI software Synthia to JW Pharma. Synthia
- Company
- Clotinab, exclusive in the bio-anti-hemolysis market
- by Nho, Byung Chul Feb 1, 2023 05:54am
- In the anti-hemorrhagic biopharmaceutical market, Korean biosimilar Clotinab is dominating the market. According to data on drug distribution performance, ISU ABXIS Clotinab's 2021 performance was 2.8 billion won, dominating the Abciximab biosimilar market. The sales of the product in 2018, 2019, and 2020 are 3,048 million won, 2,920 million
- Company
- Imfinzi expands biliary cancer indication
- by Feb 1, 2023 05:54am
- "Although there are few clinical patients, effectiveness improvement and safety performance" A new option for immuno-cancer drugs has been born in biliary tract cancer, where chemotherapy has long been the standard treatment. The medical staff said, "We improved the treatment of biliary tract cancer, which has not progressed for more than 10
- Company
- Sales of statin-ezetimibe combo rise threefold in 3 yrs
- by Chon, Seung-Hyun Feb 1, 2023 05:54am
- Statin-ezetimibe combination drugs greatly expanded their influence in Korea’s dyslipidemia treatment market. Their total prescription amount increased by over threefold in the past 5 years, and its annual market size exceeds KRW 750 billion. In the market, rosuvastatin-ezetimibe combinations drove market growth, and the bulk of generic atorvas
- Company
- Merck makes large investments in Korea’s science tech
- by Jan 31, 2023 05:59am
- With President Suk Yeol Yoon prioritizing fostering talent in science and technology as the government’s key task, one global company has attracted attention for being committed to strengthening domestic talent in science and technology in Korea. According to industry sources on the 31st, Merck Life Sciences, a global life science com
- Company
- MSD Korea to replace its leader for the first time in 2 yrs
- by Jan 31, 2023 05:59am
- The head of MSD Korea will be replaced for the first time in about two years. Kevin Peters, the current president, will leave Korea at the end of this month. According to the pharmaceutical industry on the 28th, Kevin Peters, CEO of MSD Korea, will be appointed as the general representative of the German branch from February. It has been two
